{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-037643","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.783959+00:00","generated_at":"2026-06-04T06:10:39.069220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atara posts Q4 loss $0.56/sh; tab-cel BLA submission on track for Q2 2024","bullets":["Q4 net loss $60.5M ($0.56/diluted share); FY 2023 net loss $276.1M ($2.61/diluted share).","Cash, cash equivalents and short-term investments $51.7M at Dec 31, 2023; pro-forma ~$104M after Q1 2024 proceeds.","Tab-cel BLA submission on track for Q2 2024; $20M regulatory milestone expected in April 2024.","ATA3219 lupus nephritis Phase 1 to start H2 2024, initial data H1 2025; NHL study enrolling with data Q4 2024.","Two workforce reductions: ~30% in Nov 2023 and further ~25% in Jan 2024; headcount now ~170."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-037643","json":"https://secwatch.observer/filing/0000950170-24-037643.json","markdown":"https://secwatch.observer/filing/0000950170-24-037643.md","text":"https://secwatch.observer/filing/0000950170-24-037643.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017024037643/0000950170-24-037643-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017024037643/atra-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:10:39.069220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f28219776b86ba5a7e38a310f7eaf7bd3ef7681","claim":"Atara Biotherapeutics, Inc. reported the fourth quarter and full year 2023 results: net income net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fisc, EPS $0.56 per share for the fourth quarter and $2.61 per share for the fiscal year 2023.","evidence_excerpt":"Fourth Quarter and Full Year 2023 Financial Results • Cash, cash equivalents and short-term investments as of December 31, 2023 totaled $51.7 million, as compared to $102.4 million as of September 30, 2023 and $242.8 million as of December 31, 2022 • Net cash used in operating activities was $50.4 million and $193.0 million for the fourth quarter and fiscal year 2023, as compared to $56.9 million and $270.4 million in the same periods in 2022 • Atara reported net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fiscal year 2023, respectively, as compared to $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the same periods in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017024037643/0000950170-24-037643-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2023"},{"label":"Net income","value":"net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fisc"},{"label":"EPS","value":"$0.56 per share for the fourth quarter and $2.61 per share for the fiscal year 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}